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Abstract: Immersion and intraperitoneal injection are the two most common methods used for the
vaccination of fish. Because both methods require that fish are handled and thereby stressed, oral
administration of vaccines as feed supplements is desirable. In addition, in terms of revaccination
(boosting) of adult fish held in net pens, oral administration of vaccines is probably the only feasible
method to obtain proper protection against diseases over long periods of time. Oral vaccination is
considered a suitable method for mass immunization of large and stress-sensitive fish populations.
Moreover, oral vaccines may preferably induce mucosal immunity, which is especially important
to fish. Experimental oral vaccine formulations include both non-encapsulated and encapsulated
antigens, viruses and bacteria. To develop an effective oral vaccine, the desired antigens must be
protected against the harsh environments in the stomach and gut so they can remain intact when they
reach the lower gut/intestine where they normally are absorbed and transported to immune cells. The
most commonly used encapsulation method is the use of alginate microspheres that can effectively
deliver vaccines to the intestine without degradation. Other encapsulation methods include chitosan
encapsulation, poly D,L-lactide-co-glycolic acid and liposome encapsulation. Only a few commercial
oral vaccines are available on the market, including those against infectious pancreatic necrosis virus
(IPNV), Spring viremia carp virus (SVCV), infectious salmon anaemia virus (ISAV) and Piscirickettsia
salmonis. This review highlights recent developments of oral vaccination in teleost fish.
Keywords: oral vaccination; fish; teleost; mucosal immunity
1. Introduction
It is suggested that oral immunization evokes a mucosal response, facilitated by the
production and secretion of mucosal immunoglobulins (Igs)—where IgT (IgZ in zebrafish
(Danio rerio)) is central [1–3]. The produced IgT may act as arresting molecules (opsonins)
that facilitate further degradation of or controlling the microbes [4]. The amount of Igs in
normal serum differs between fish species, where, for example, Atlantic salmon (Salmo salar)
serum contains approximately 1 mg mL−1 Igs, whereas haddock (Melanogrammus aeglefinus)
and cod (Gadus morhua) serum have approximately 7 and 12 mg mL−1 Igs, respectively.
The latter fish species lack genes for MHC class II—which suggests that these two species
rely much on “natural” antibodies for protection [5]. The level of Igs in cod serum is
quite similar to those found in ray-finned fish [6]. In a recent study, the level of IgT in
serum of rainbow trout (Oncorhynchus mykiss) was calculated to be more than 600× lower
(8.62 µg mL−1 in serum) than for IgM, whereas in the nasal mucus, it was approximately
164× lower (1.7 µg mL−1) [7]. To our knowledge, the concentration of gut mucus IgM and
IgT following oral vaccination has not been evaluated before. Based on present findings,
one can suggest that IgT indeed is a mucosal Ig, but it remains to be shown whether IgT is
a mucosal correlate of protection. Nevertheless, oral vaccination is an attractive modality
to immunize fish for increased protection against pathogens. Since the last review article
on oral vaccination by Mutuloki et al. (2015) [1], there have been several advances, which
are highlighted in the current overview together with previously published data.
Int. J. Mol. Sci. 2021, 22, 10932. https://doi.org/10.3390/ijms222010932 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 10932 2 of 19
2. Bacterial Diseases
2.1. Vibriosis
Vibriosis is one of the most severe infectious diseases affecting marine fish in trop-
ical and subtropical zones of the world. Its pathogens mainly include Vibrio harveyi,
Vibrio parahaemolyticus, Vibrio alginolyticus, and Vibrio anguillarum. Mao et al. (2011) used
outer membrane protein K (OmpK), one of the significant outer-membrane proteins of
V. harveyi, as an oral vaccine [8]. The molecule was expressed in the yeast Pichia pastoris
and encapsulated in alginate microspheres. The vaccine was fed to Japanese sea bass
(Lateolabrax japonicus). A significant antibody level against OmpK was elicited and the
challenge of vaccinated fish revealed protection against the pathogen. V. anguillarum
is the main causative agent of vibriosis in cultured sea bass. Galindo-Villegas et al.
(2013) used a commercial sea bass oral vaccine against V. anguillarum and improved
it with recombinant sea bass tumor necrosis factor alpha (rTNFα) as an adjuvant [9].
Orally immunized European sea bass (Dicentrarchus labrax) conferred protection against
V. anguillarum challenge throughout a short time period. Moreover, fish that received
adjuvant + antigen significantly extended the response. In both cases, achieved protection
was independent of serum IgM. However, IgT transcripts were found to increase in the
gut of rTNFα-treated fish. Fish treated with rTNFα also showed a dramatic change in their
T lymphocytes distribution and localization in the gut mucosal tissue. In another study
by Sarropoulou et al. (2012), a commercial oral vaccine against V. anguillarum (Aquavac
Vibrio Oral, ISPAH) was fed for 10 days to European sea bass and boosted four months
later [10]. The evaluation revealed specific immune gene expression profiles in the gut.
Turbot (Scophthalmus maximus) is one of the most important commercial fish species
worldwide because of its rapid growth and high market value. V. anguillarum is caus-
ing serious infections in this species. Gao et al. (2016) developed carboxymethyl chi-
tosan/chitosan nanoparticles (CMCS/CS-NPs) loaded with extracellular products (ECPs)
of V. anguillarum for oral vaccination. Immunized fish showed elevated specific antibody
levels and higher concentrations of lysozyme and complement activities compared with
stimulation with soluble ECP. A DNA vaccine was constructed using the ompK gene
of V. parahaemolyticus encapsulated in chitosan nanoparticles for oral delivery to black
seabream, Acathopagrus schlegelii Bleeker [11]. The ompK gene transcripts were found in the
mid-intestine, liver, kidney and muscle after administration, and the expression evoked
an immune response that protected fish against infection (RPS of 72.3%). In a study by
Li et al. (2016) goldlined/silver sea bream juveniles (Sparus sarba) were fed with pellets
containing a vaccine of formalin-killed V. alginolyticus [12]. Three weeks after booster vacci-
nation, fish were challenged with pathogenic V. alginolyticus. Although oral vaccination
could not offer protection as good as that of injection vaccination, oral vaccination appeared
effective for protecting silver sea bream [12].
2.2. Motile Aeromonad Septicemia (MAS)
Aeromonas hydrophila is a Gram-negative, facultative anaerobic motile bacterium that
is the causative agent of motile Aeromonas septicemia (MAS) in fish. The South American
catfish, the hybrid surubim (Pseudoplatystoma corruscans × Pseudoplatystoma reticulatum),
has a high economic value because of its excellent flavor and spineless fillets. A. hydrophila
is a serious pathogen of this species. Do vale Pereira et al. (2015) determined the effi-
cacy of different inactivated A. hydrophila vaccines administered intraperitoneally with
or without an oral booster [13]. Fish treated both intraperitoneally and orally boosted
with bacterin + toxoid (inactivated extracellular products) showed the lowest cumulative
mortality (10%) when intraperitoneally challenged with A. hydrophila. Dubey et al. (2016)
used the cloned outer membrane protein W (OmpW) of A. hydrophila as a vaccine compo-
nent in rohu (Labeo rohita Hamilton) and encapsulated it in poly D,L-lactide-co-glycolic acid
(PLGA) nanoparticles for oral vaccination [14]. Two antigen doses were orally administered.
The high antigen dose resulted in higher antibody levels than the low antigen dose after
oral vaccination and corresponded with the relative percent survival (RPS).
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2.3. Edwardsiellosis
Chatakondi et al. (2018) evaluated the efficacy of an oral live-attenuated Edwardsiella
ictaluri vaccine against enteric septicemia of catfish (ESC) in channel (Ictalurus punctatus)
and hybrid catfish (Ictalurus punctatus × Ictalurus fucatus) [15]. Channel catfish is the
single largest aquacultured species in the USA. Enteric septicemia of catfish (ESC) and
columnaris disease are two of the most economically important bacterial diseases affecting
the catfish industry. Thirty-five days post-vaccination, fish were challenged with viru-
lent E. ictaluri and mortality was examined for 30 days post-challenge. The mortality
of non-vaccinated hybrids (85%) and non-vaccinated channel catfish (75%) was signifi-
cantly greater than all groups of vaccinated. In channel catfish, mortality in the lowest
dose of vaccine was 26.6% (RPS 61.9%) and significantly higher than in the highest dose
group (14.1%, RPS 80.6%). Mortality of orally vaccinated hybrid catfish ranged between
10.4%, (RPS 87.4%) and 14% (RPS 83,5%) [15]. Recombinant outer membrane protein A
(rOmpA) of Edwardsiella tarda was encapsulated in chitosan polymeric nanoparticles (NPs)
and used for oral vaccination of fringed-lipped peninsula carp (Labeo fimbriatus) [16].
All vaccines were administered in the feed for 21 days. The fish were challenged with
a pathogenic strain of E. tarda 51 days post-vaccination. The NP-rOmpA vaccine pro-
duced higher antibody levels and had superior protection than the inactivated whole
cell vaccine of E. tarda. Kole et al. (2018) report of a bicistronic DNA vaccine containing
glyceraldehyde-3-phosphate dehydrogenase gene (gapdh) of E. tarda with an additional
immune adjuvant gene (interferon gamma gene (ifng)) (gapdh + ifng) nanoconjugated with
chitosan nanoparticles [17]. The vaccine was given to rohu fingerlings in the feed for
14 days, and a RPS of 81,82 % was obtained. This group also showed significant upregu-
lation of immune gene transcripts like ighc (IgM heavy-chain constant-region), inos, tlr22,
nod1 and il1b.
2.4. Yersiniosis
Yersinia ruckeri, a Gram-negative member of the family Enterobacteriaceae, is
the causative agent of enteric redmouth disease (ERM) and yersiniosis in salmonids.
Ghosh et al. (2016) used a microencapsulated Y. ruckeri vaccine formulation for both im-
mersion and oral administration to first-feeding Atlantic salmon [18]. Both oral and
oral + dip groups demonstrated moderate protection when challenged (RPS of 29.4% and
51%, respectively). Protection was even lower for fish dipped (immersion vaccinated)
one and two times (RPS 20.4% and 16.7%, respectively) which were immunized only
via immersion.
2.5. Lactococcosis/Streptococcosis
The Gram-positive bacteria, Streptococcus iniae and Lactococcus garviae, are known as
two major species of streptococcal infections in many fish species, particularly salmonids.
Romalde et al. (2004) studied both non-encapsulated and alginate encapsulated oral vac-
cines against lactococcosis in rainbow trout. The encapsulated vaccine administered orally
resulted in a RPS of 50% [19]. The same vaccine was used as a booster immunization after
a priming intraperitoneal vaccination. Halimi et al. (2018) used Eudragit L30D-55-coated
vaccine (polymer-drug release coating containing formalin-inactivated bacteria) pellets for
vaccination of rainbow trout against S. iniae and L. garviae [20]. Vaccination was conducted
for 14 days, and 60 days thereafter, the fish were challenged with either L. garviae or S. iniae.
Observed survival percentages were 72% (L. garviae) and 85% (S. iniae). Another fish
species that have been shown to suffer from streptococcosis is tilapia. Red hybrid tilapia
(Oreochromis sp.) was immunized by an inactivated recombinant vaccine expressing the
cell wall surface anchor family protein of Streptococcus agalactiae. Orally immunized fish
developed a strong and significantly high IgM antibody response in serum, mucus and
gut lavage fluid samples. The rate of survivors was 70% [21]. A feed-based oral vaccine
of formalin-fixed S. agalactiae and in addition a vaccine containing Freund’s incomplete
adjuvant were prepared [22]. Red tilapia were fed the respective vaccines and boosted
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orally at day 14. Four weeks after the start of the experiment, fish were intraperitoneally
challenged with S. agalactiae. The adjuvanted group showed a significantly higher survival
rate. In a study by Hayat et al. (2021), red hybrid tilapia were fed a formalin-killed oral
S. iniae vaccine [23]. All vaccinated groups showed a significant increase in anti-S. iniae
IgM levels in serum, mucus and gut-lavage. Enhanced protection was achieved after a
booster dose. The study of Monir et al. (2020) focuses on the effectiveness of a newly
developed feed-based killed bivalent vaccine against S. iniae and A. hydrophila in hybrid
tilapia (Oreochromis mossambicus × O. niloticus) [24]. The vaccine was orally administered
on days 0, 14 and 42 days. Challenge tests were performed 70 days post-vaccination with
single bacterial infections and co-infections. Results showed a significant protection after
the coinfection challenge.
2.6. Furunculosis
Furunculosis is a highly contagious disease that affects fish of all ages. The infec-
tion causes high mortality in salmonids and some other species of fish like the goldfish
(Carassius auratus). Maurice et al. (2004) cloned and modified the A-layer protein of atypical
Aeromonas salmonicida by genetic fusion of the protein transduction protein (MTS) derived
from Kaposi fibroblast growth factor (At-MTS) [25]. Both At-R (A-layer) and At-MTS were
encapsulated in alginate beads and fed to goldfish. Vaccine-fed goldfish demonstrated in-
creased antibody titers. In spite of this, vaccinated fish did not demonstrate resistance to in-
fection with atypical A. salmonicida. Furunculosis caused by A. salmonicida ssp. salmonicida
is one of the most important bacterial diseases affecting cultured and wild salmonid fish,
and also in non-salmonid marine species such as turbot (S. maximus), gilthead sea bream
(Sparus auratus) and sea lamprey (Petromyzon marinus). A commercial furunculosis vac-
cine induced protection in turbot after injection, with RPS-values of 72–99% 120 days
post-immunization [26]. Six months after immunization the RPS levels declined to 50–52%.
An oral boost after the primary injection vaccination did not enhance protection. The
response of isolated gut leucocytes to four bacterins of A. salmonicida prepared from differ-
ent strains, combinations and strains grown in different environments in comparison to a
Y. ruckeri bacterin was studied by Attaya et al. (2020) [27]. A wide array of immune gene
transcripts was modulated by the bacterins. The gut-associated lymphoid tissue (GALT)
leucocyte responses were sensitive enough to distinguish the different bacterial species,
strains and membrane proteins.
2.7. Francisellosis
Members of the genus Francisella are small Gram-negative facultative intracellular
bacteria that cause francisellosis in a wide variety of fish species worldwide. Francisella
noatunensis subsp. orientalis (Fno) has been recently described as a warm-water pathogen of
tilapia Oreochromis spp. Hoare et al. (2021) used an existing bacterin to optimize a mucosal
vaccine against Fno in Nile tilapia (Oreochromis niloticus) with mucosal adjuvants (IMS 1312
VG PR; a Montanide™ variant) [28]. Fish fry received the vaccine with oral gavage and
were boosted once. Specific IgM titers were significantly elevated in serum and mucus in
fish given the highest dose.
2.8. Piscirickettsiosis/Salmonid Rickettsial Septicaemia
One of the main pathogens that plagues salmonid culture during the on-growing
phase is Piscirickettsia salmonis, the causal agent of salmonid rickettsial septicaemia (SRS)
or piscirickettsiosis. This Gram-negative bacterium, fastidious intracellular pathogen,
originally isolated from a coho salmon (Oncorhynchus kisutch) in southern Chile, produces
a systemic infection characterized by colonization of several organs, including kidney,
liver, spleen, intestine, brain, ovary and gills. SRS is the infectious disease that produces
the highest losses in the Chilean salmon industry. The effect of alginate-encapsulated
P. salmonis antigens (AEPSA) incorporated in the feed as an oral vaccine in Atlantic salmon
(Providean Aquatech 1, Anasac, Chile) was studied by Sotomayor-Gerding et al. (2020) [29].
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The oral vaccine produced an acquired immune response (IgM) similar to the injectable
vaccine at 840 days degree. Tobar et al. (2015) studied the vaccination program against
P. salmonis and infectious salmon anemia virus to maintain long-term protection in farmed
salmonids in 622 Chilean farms from 2011–2014 [30]. All fish were vaccinated first by the
intraperitoneal injection of oil-adjuvanted antigen and then by oral vaccines as a booster
vaccination. A close association between antibody levels and protective status was found.
The results of this study demonstrated that, in the field, several oral immunizations are
essential to uphold a high level of specific anti-pathogen antibodies and the protective
status during the whole production cycle [30].
An overview of oral vaccines against bacterial diseases is found in Table 1.
Table 1. Overview of recent oral vaccination trials against bacterial diseases.
Disease Pathogen Fish Species Vaccine Reference
Vibriosis
V. anguillarum Rainbow trout Anti-V. anguillarum antiserum [31]
Turbot Extracellular products [32]
V. alginolyticus Silver sea bream Inactivated [12]
V. anguillarum European sea bass Aquavac Vibrio oral,ISPAH, commercial [9]
V. parahaemolyticus Black seabream DNA in chitosan particles [11]
V. anguillarum European sea bass Commercial AquavacVibrio oral [10]
V. harveyi Sea bass Recombinant [8]
Motile aeromonad
septicaemia (MAS) A. hydrophila
LPS+S-layer protein [33]
Surubim hybrid Inactivated bacterin [13]
Rohu Recombinant [14]
Haemorrhagic septicaemia Carp A. hydrophila ghosts [34]
Enteric septicemia of
carp (ESC) E. ictaluri Channel & hybrid catfish Live attenuated [15]
Edwardsiellosis E. tarda
Olive flounder Mutated bacteria [35]




protein A in chitosan [16]
Yersiniosis
Y. ruckeri







Lactococcosis Streptococcosis L. garviae S. iniae Eudragit-coated bacteria [20]
Int. J. Mol. Sci. 2021, 22, 10932 6 of 19
Table 1. Cont.
Disease Pathogen Fish Species Vaccine Reference
Streptococcosis
S. agalactiae
Nile tilapia Live attenuated/DNA vaccine [37]
Red tilapia Inactivated [22]
S. iniae Channel catfish Recombinant protein inalginate/chitosan [38]
S. agalactiae Tilapia
Surface immunogenic protein
















Turbot Commercial furunculosisvaccine, Aquavac Furovac [26]
Salmon rickettsial
septicaemia (SRS) P. salmonis Atlantic salmon
Providean Aquatech 1 Anasac
in alginate [29]







trout and coho salmon Commercial vaccines [30]
Epizootic ulcerative syndrome A. veronii Common carp Recombinant OmpAI [41]
Enteric septicaemia of catfish E. ictaluri Channel catfish Live attenuatedE. ictaluri [42]
3. Viral Diseases
3.1. Infectious Pancreas Necrosis (IPN)
IPN is a highly infectious viral disease, causing high mortalities in fish species world-
wide. The IPNV belongs to the family Birnaviridae, genus Aquabirnavirus with a biseg-
mented double-stranded RNA genome. Segment A is encoding the two major structural
proteins of the virus (VP2 and VP3). VP2 is a protective antigen that induces virus neutral-
izing antibodies. Ahmadivand et al. (2017) developed a DNA vaccine encoding the VP2
gene of IPNV and encapsulated it in chitosan/tripolyphosphate (CS-TPP) nanoparticles
and alginate microparticles [43]. Rainbow trout fry (weight 3 g) were orally immunized
with feed pellets containing the nanoparticles or microparticles for 90 days. 45 days after
vaccination start the fish were challenged by intraperitoneal injection of a virulent isolate
of the IPNV. Fish vaccinated with alginate microparticles containing 10 and 25 mg of
the VP2 DNA vaccine gave cumulative mortalities of 24% and 10% resulting in RPS of
59% and 82% respectively. Cumulative mortalities in the CS-TPP-groups were 30% and
17% with corresponding RPS of 47% and 70 % for the 10 and 25 mg DNA vaccine groups,
respectively [43]. De las Heras et al. (2010) found that a VP2 capsid gene encapsulated
in alginate microcapsules gave RPS of 80% when administered orally to brown trout
(Salmo trutta) when challenged with IPNV 15 and 30 days after vaccine delivery [44].
Ballesteros et al. (2012) showed that oral VP2 vaccine could mimic both the time-course
and the organ (head kidney, spleen, intestine, pyloric ceca, thymus) profiles of transcripts
obtained after IPNV infection [45], but transcriptional levels were lower in VP2-vaccinated
than in IPNV-vaccinated trout. They suggested that the mechanisms by which alginate-oral
DNA-vaccination induces protection were similar to the defense mechanisms induced by
IPNV-infection. In response to oral vaccination with the VP2 DNA vaccine encapsulated in
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alginate, the B cell response in five different segments of the rainbow trout digestive tract
was studied [46]. The pyloric ceca region was the area in which the major recruitment of
B cells was demonstrated both IgM+ and IgT+ intraepithelial lymphocytes [46]. Boosting
may be a good method for enhancing or extending protection.
One year after intraperitoneal injection with an oil-adjuvanted IPN-vaccine, Atlantic
salmon post-smolts were orally boosted by alginate-encapsulated IPNV antigen (ENCAP)
or soluble antigen [47]. This was done twice, seven weeks apart. Compared to controls, fish
fed with ENCAP had a significant increase in serum antibodies following the first boost, but
not after the second. Results of this study suggest that parenteral prime vaccination with
oil-adjuvanted vaccines and followed by oral boost with ENCAP gives an augmentation of
the systemic immune response. Symmetrical prime and boost oral vaccination with ENCAP
results in augmentation of mucosal immune response. Symmetrical priming and boosting
orally with soluble antigens resulted in the induction of systemic immune tolerance [47]. A
liposomal DNA vaccine coding for the immunogenic region of the IPNV VP2 capsid protein
(lipoplex) induced detectable levels of VP2-specific antibodies and conferred significant
protection following IPNV challenge with RPS of 58.2% for single-dose and 66% for double-
dose orally administration in Atlantic salmon [48]. A DNA vaccine based on the VP2 gene
was given orally to rainbow trout through the feed. A strong protection was obtained
significantly upregulating ifn1, ifng, mx1, il8 (cxcl8), il12, igm (constant region of the heavy
chain) and igt (constant region of the heavy chain) [49].
3.2. Viral Nervous Necrosis
Viral nervous necrosis (VNN), also known as viral encephalopathy and retinopa-
thy (VER), is one of the most serious infectious diseases affecting marine aquaculture.
Since its first description in the late 1980s, many economically relevant fish species has
proven to be susceptible to the disease, such as European sea bass, Asian sea bass
(Lates calcarifer), groupers (Ephinephelus spp.), striped jack (Pseudocaranx dentex), Sene-
galese sole (Solea senegalensis), turbot, Atlantic halibut (Hippoglossus hippoglossus) and
Atlantic cod. Chen et al. (2011) focused on the development of a new oral vaccine that could
provide sufficient, earlier protection in the orange-spotted grouper (Epinephelus coioides) [50].
V. anguillarum was used as an antigen expression host due to its immune-stimulatory
capability. An expression vector containing heat shock protein 60 gene (hspd) (named groE in
orange-spotted grouper) as an inducible promotor was constructed to express recombinant
NNV coat protein. The recombinant V. anguillarum was inactivated and encapsulated in
Artemia nauplii to formulate an oral vaccine [51]. A higher specific antibody titer against
NNV was observed in the first week after inoculation [50]. In addition, a higher survival
rate compared to an equal dose of an E. coli-based oral vaccine was found. Lin et al. (2007)
did a similar study in grouper larvae with a recombinant NNV-capsid protein. After oral
administration, the vaccine was absorbed in the hindgut, induced anti NNV VP specific
antibodies and resulted in a RPS of 64.2–69.5% [52].
Kai et al. (2014) performed an interesting study on immune gene expression in grouper
larvae after immunization with binary ethylenimine inactivated NNV [53]. Both bath and
oral vaccination triggered gene expression of both humoral and cellular immunity. The
red-spotted grouper nervous necrosis virus (RGNNV) is the most common species of NNV
worldwide. Cho et al. (2017) developed a recombinant Saccharomyces cerevisiae RGNNV
capsid protein [54] as an oral vaccine in convict grouper (Hyporthodus septemfasciatus) [55].
The oral vaccinated fish produced serum RGNNV neutralizing antibody titers >103 sus-
tained for at least 95 days post-immunization. In response to a challenge with RGNNV,
the fish showed significantly reduced mortality and had reduced brain RGNNV titers [55].
Furthermore, an experimental oral vaccine was made from recombinant orange-spotted
NNV capsid protein produced in Escherichia coli and then assembled into virus-like par-
ticles (VLPs). After executive feeding of the VLPs and experimental challenge, the RPS
was calculated to be 52.3% [56]. In another study, RNA2 capsid protein gene of NVV
was encapsulated in chitosan-tripolyphosphate nanoparticles and given by feeding. After
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challenging the Asian sea bass with intramuscular injection of NVV, the orally vaccinated
fish exhibited a RPS of 60% [57].
Cho et al. (2018) expressed NNV coat protein in tobacco chloroplasts and used it as an
oral vaccine in seven-band grouper (Epinephelus septemfasciatus). Fish developed signifi-
cantly higher antibody titers against the NNV coat protein and were partially protected
against viral challenge [58]. An oral vaccine against VNN supplemented with capsaicin
conferred protective immunity on seven-band grouper fed for seven days and challenged
at 21 days after the start of immunization [59]. Valero et al. (2016) used an oral chitosan-
encapsulated DNA vaccine (CP-pNNV) for the nodavirus to protect European sea bass
against VNN [60]. The vaccine failed to induce serum circulating or neutralizing specific
antibodies (IgM). However, the vaccine upregulated the expression of genes related to
cell-mediated toxicity (CMC) and the interferon pathway. In addition, three months after
vaccination, challenged fish showed a retarded onset of fish death and lower cumulative
mortality with a RPS rate of 45% [60].
3.3. Grass Carp Reovirus (GCRV)
Haemorrhagic disease caused by grass carp (Ctenopharyngodon idella) reovirus (GCRV)
results in a tremendous loss in the grass carp industry. GCRV is a double-stranded RNA
virus belonging to the genus Aquareovirus, family Reoviridae. The Gram-positive soil
bacterium Bacillus subtilis is a non-pathogen, and its spore form is currently used as a
probiotic for both human and animal consumption. B. subtilis spores have been shown to
be able to protect surface-displayed heterologous antigens against degradation. Two grass
carp-sourced B. subtilis spore-based vaccines (GC5-VP4 and GC5-NS38) were constructed
and their potential as oral candidate vaccines against GCRV II was investigated [61]. Both
VP4 and NS38 proteins of GCRV II were efficiently displayed on the spore surface of
B. subtilis GC5. After oral administration, both vaccines increased the survival rate of grass
carp against GCRV II with relative percent survival rates of 30% and 36.4%, respectively.
Another recent study by Sun et al. (2020) of the same species used Cot B and Cot C
coat anchors for grass carp reovirus recombinant VP7 antigen [62]. In fish orally vaccinated
with the VP7-expressing spores, immunogenicity and protection were augmented. The
IgM titers were significantly increased on day 7 and reached peaks on day 14, then dropped
from day 21 to day 28.
Another oral subunit vaccine against GCRV was constructed for the same species [63].
Outer capsid proteins VP5 and VP7 expressed in E. coli were coated on pellets and fed
to grass carps for 21 days. Specific antibody responses could be detected in sera and
significantly lower accumulative post-vaccination mortality rates were achieved.
3.4. Spring Viremia of Carp (SVC)
Spring viremia of carp virus (SVCV) characterized as a member of the genus Spriv-
ivirus of the family Rhabdoviridae is a linear single-stranded negative RNA virus causing
high mortality and infectious disease accompanied with typically acute hemorrhage symp-
toms in cyprinids, in particular common carp. Cui et al. (2015) developed a genetically
Lactobacillus plantarum co-expressing glycoprotein (G) of SVCV and ORF81 protein of koi
herpesvirus (KHV) [64]. The recombinant plasmid was electroporated into L. plantarum.
Common carps (Cyprinus carpio) and koi carps (Cyprinus carpio koi) were orally immunized
with L. plantarum containing the expressed proteins. This vaccination strategy induced sig-
nificant levels of IgM and reduced viral loads after viral challenge. Also, an effective protec-
tion rate of 71% in vaccinated carps and 53% in vaccinated koi until days 65 post-challenge
was obtained [64]. A chitosan-alginate microcapsule probiotic L. plantarum expressing
G protein of SVCV was constructed [65]. Common carps were primarily vaccinated by
oral administration and after 14 days a booster vaccine was given and after 28 days, a
second booster vaccine was administered. A significantly higher level of antigen-specific
IgM antibodies was elicited and the vaccine provided effective protection against SVCV
infection 42 days after the primary vaccination [65].
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3.5. Viral Haemorrhagic Septicaemia
Viral haemorrhagic septicemia (VHS) afflicts over 50 species of freshwater and marine
fish of the Northern Hemisphere. The viral haemorrhagic septicaemia virus (VHSV) is an
enveloped ribonucleic acid (RNA) virus that belongs to the genus Novirhabdovirus of the
family Rhabdoviridae. Different strains of the virus occur in different regions and affect
different species. There are no signs that the disease affects human health. VHS is also
known as Egtved disease. In a study by Kim et al. (2019), cholera toxin B subunit (CTB)-
fused recombinant viral haemorrhagic septicaemia virus glycoproteins (rec-VHSV-GPs)
were expressed in tobacco, Nicotiana benthamiana and used as a combination vaccine
(intraperitoneal and oral) in olive flounder (Paralichthys olivaceous) [66]. The antibody titers
were significantly increased and after viral challenge fish were protected with a significantly
lower mortality rate.
3.6. Infectious Hematopoietic Necrosis (IHN)
Infectious hematopoietic necrosis virus (IHNV) is responsible for important losses
in the salmonid farming industry worldwide. IHNV is a non-segmented, enveloped,
single-stranded, negative-sense RNA virus belonging to the genus Novirhabdovirus in the
family Rhabdoviridae. Previous studies demonstrated that the IHNV G protein is the only
viral protein capable of inducing a neutralizing antibody response to IHNV. In a IHNV
vaccination study, a DNA vaccine encoding the IHNV G protein was encapsulated into
alginate microspheres and orally administered to rainbow trout. IHNV G transcripts were
detected in gills, spleen, kidney and intestinal tissues of vaccinated fish [67]. The oral
route was found to require approximately 20-fold more plasmid DNA than the injection
route to induce the expression of significant levels of ihng transcripts in the kidney and
spleen. When vaccinated fish were challenged by immersion with live IHNV, evidence
of a dose-response could be observed. The protective effects were partial, but significant
differences in cumulative mortalities among the orally vaccinated fish and the unvaccinated
or empty plasmid-vaccinated were observed.
3.7. Infectious Salmon Anaemia
Infectious salmon anaemia (ISA) is an infectious viral disease of Atlantic salmon. The
disease was first reported in Norway in 1984, but has since been reported in Canada, the
USA, the Faroe Islands, Ireland and Scotland. Atlantic salmon is the only susceptible species
known to develop clinical disease, but ISA virus can replicate in rainbow trout and sea
trout. In the following experimental approach, a non-adjuvanted ISAV vaccine (inactivated
virus) and a vaccine based on ISAV + plasmid DNA encoding the replicase of alphavirus
protein as adjuvant were encapsulated in chitosan nanoparticles—and administered orally
to Atlantic salmon [68]. Vaccination with the non-adjuvanted vaccine (inactivated virus)
resulted in modest protection, while the adjuvanted gave a RPS of 77%.
3.8. Iridoviral Disease (IVD)
Iridovirus is a double-stranded DNA virus of the Iridoviridae family. The main
pathogen is the Megalocytivirus. This is further composed of infectious spleen and kidney
necrosis virus (ISKNV) and red sea bream iridovirus (RSIV). In the study of Seo et al. (2013),
a recombinant major capsid protein (rMCP) of rock bream iridovirus (RBIV) was expressed
in yeast. Rock bream (Oplegnathus fasciatus) immunized orally with rMCP underwent a
successful induction of specific antibodies and was protected against viral challenge [69].
In the study by Shin et al. (2013) a recombinant major capsid protein (rMCP) of rock
bream iridovirus was expressed in transgenic rice callus. Rock bream immunized orally
with rMCP underwent successful induction of antibodies and was protected against viral
challenge [70]. An overview of oral vaccines against viral diseases is found in Table 2.
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Table 2. Overview of recent oral vaccination trials against viral diseases.
Disease Pathogen Fish Species Vaccine Reference










Inactivated or live IPNV [71]
VP2 DNA vaccine [48]
Brown trout &
Rainbow trout DNA [44]
Nervous necrosis Red-spotted grouperNNV (RGNNV)
Red-spotted
Grouper Recombinant [58]
Nervous necrosis NNV Orange-spottedGrouper Subunit [50]
Viral haemorrhagic disease Grass carp rheovirusII (GCRVII) Grass carp Recombinant
[72]
Spring viremia of carp (SVCV) SVCV Common carp [64]
VHS, IHN VHS virus, IHN virus Rainbow trout Attenuated [73]
Viral haemorrhagic septicaemia VHS virus Olive flounder Recombinant [66]
Viral nervous necrosis (VNN) NNV
Grouper
Inactivated betanodavirus [53]
Viral nervous necrosis VNNV
Recombinant
[52]




Viral nervous necrosis Piscine nodavirus/Betanodavirus Inactivated [59]
Viral nervous necrosis (VNN) Nodavirus Orange-spottedgrouper Recombinant [56]
Viral nervous necrosis (VNN) Nodavirus European sea bass DNA in chitosan [60]
Viral nervous necrosis (VNN) Nodavirus Asian sea bass DNA in chitosan-tripolyphosphate [57]
Infectious salmon anaemia ISAV Atlantic salmon Inactivated [68]
Rock bream
iridovirus (RBIV) Rock bream Recombinant major
capsid protein
[69]
Rock bream iridovirus [70]
Infectious hematopoietic necrosis IHNV Rainbow trout Yeast vaccine EBY100/pYD1-bi-G [74]
Grass carp hemorrhagic disease Grass carp reovirus Grass carp Recombinant [62]
4. Parasitic Diseases
ClonorChiasis
Since 1998 where Speare et al. [75] showed that rainbow trout orally intubated with
gill preparation containing Loma salmonae exhibited a certain protection level against
reinfection, no major breakthrough of oral vaccines against parasites has occurred. The
lack of breakthroughs is also mirrored in the review article by Mutoloki et al. (2015) [1].
However, some recent reports suggest that novel vaccine vehicles may be a solution to
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induce antiparasitic effects upon oral delivery. Clonorchiasis (Clonorchis sinensis) is a
serious zoonotic parasitic disease in South Asian regions such as China, Korea, Vietnam
and Russia. Approximately 15 million people are infected with this tropical disease globally.
Grass carps are the main species of freshwater aquaculture in China with high economic
value [76]. People infected with C. sinensis are mainly due to eating raw or undercooked
freshwater fish containing infective metacercariae, so cutting off the transmission route
by interrupting the formation of metacercaria in freshwater fish would be an effective
strategy to control clonorchiasis. The Gram-positive B. subtilis spores have been shown as
an ideal vaccine delivery system and the C. sinensis enolase (CsENO) was used as a vaccine
candidate. Grass carps were fed spores with CsENO and the fish developed specific IgM
levels in serum, intestine and skin mucus in addition to upregulation of central innate and
adaptive immunity molecules [76]. In a recent study by Sun et al. (2020b) paramyosin of
C. sinensis (CsPmy) was expressed on the surface of B. subtilis spores [61]. The recombinant
spores were incorporated in pellets and administered orally to grass carp. This induced
both systemic and local mucosal immune responses and elicited promising protective
effects in grass carp. Ichthyophthirius multifiliis is a protozoan that invades the gills and skin
surfaces of freshwater fish. In the study by Yao et al. (2016) L. plantarum NC8 was used as a
host to express the mobilization antigens—potential vaccine candidates for prevention of
the “white spot” disease (Ichthyophthiriosis). Goldfish were orally immunized with the
recombinant vaccine. The antibody level in the blood and skin was increased. In addition,
the expression of igm, c3 and mhc1 genes was significantly upregulated, and after the
challenge the average survival rate was elevated. Heidarieh et al. (2015) reported a
nanoparticle system for oral delivery of the vaccine. Irradiated I. multifiilis (inactivated
trophonts) were encapsulated in alginate particles and given orally to rainbow trout. Fish
were subsequently challenged with I. multifiliis. Differences in hematocrit, red blood cells
and biochemical levels (total plasma protein, plasma alkaline phosphatase and plasma
glucose levels) were tested—in the form of preclinical assessment. Table 3 gives an overview
of oral vaccines against parasites, examined in experimental trials.
5. Model Antigens
Kwon et al. (2019) used an oral vaccination platform of microalgae for the delivery of
recombinant drugs. The green fluorescent protein (GFP) was bioencapsulated and orally
delivered to zebrafish. The GFP was clearly observed in the intestinal tissues and the
blood [77]. Plasmid pCMVb (lacZ reporter gene encoding for E. coli β-galactosidase) was
encapsulated in chitosan nanoparticles and orally intubated in gilthead sea bream [78]. The
lacZ gene expression (β-galactidase activity) could be detected in fish tissues following oral
administration for up to 60 days. The results suggest that chitosan nanoparticles enabled
efficient oral delivery of pDNA followed by organ migration and expression. In comparison,
after parenteral administration, reporter gene expression was mostly restricted to adjacent
tissues of the injection site. Organ distribution of the gene expression was more evident
after oral administration in the gut, liver and muscle. Moreover, the IgM response was
more intense after oral delivery of the plasmid [78]. The findings of Sato & Okamoto (2008)
strongly suggest that oral administration of hapten-modified cellular antigens to ginbuna
crucian carp (Carassius auratus langsdorfii) can induce antigen-specific cytotoxic cells that
are capable of recognizing antigens in a MHC-restricted manner, and also of inducing
cytotoxic memory response [79]. An overview of oral vaccines using model antigens is
found in Table 3.
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Table 3. Overview of recent oral vaccination trials against a parasitic disease and experiments using model antigens.
Disease Pathogen Species Vaccine Reference












Red crucian carp OVA model antigen [83]
Zebrafish GFP in Chlamydomonas reinhardtii [77]
6. Intestinal Immune Defense
6.1. Immune Molecules in Mucus and Bile
In a recent study, a proteomic approach was performed to elucidate the constituents
of intestinal mucus and bile (tilapia) with a focus on immune-related molecules [84]. The
study revealed that the mucus constituted of molecules associated with pattern recognition,
antigen presentation, inflammatory cytokines and receptors, adaptors, effectors and signal
transduction, T- and B-cell antigen activation and diverse molecules related to immune
response. On the other hand, the bile contained proteins related to mainly acute phase
response and complement cascade [84]. This suggests that these two different secretions
possess specialized functions. We may further suggest that the immune molecules in bile
excretions may have a more arresting function (complement) than signaling (and effector)
function posed by mucous secretions in the intestine.
6.2. Anatomical Distribution of Immune Cells in the Gut
During recent years, many excellent review articles describing the fish’s intestinal
immunity have been published [85–91]. It is acknowledged that the intestine is composed of
mainly enterocytes and goblet cells [92,93], with interstitial or associated T- and B-cells [94].
It is not fully clear whether other cell types exist. There are no indications that confined
lymphoid structures are present along the gastrointestinal tract of bony fish. However, a
lymphoid structure in the cloacal region was recently discovered in Atlantic salmon [95].
This may be the same as Inami et al. (2009) found in Atlantic cod—although the work on
cod did not describe the anatomical localization properly [96]. This lymphoid cell aggregate
may be active in antigen capture and immune response. Through gene expression studies,
genes encoding il1b, cxcl8, il10, hamp, and ccl19 were found. These genes likely play roles at
least in the innate immunity.
An interesting approach to dissect the different cell population in zebrafish intestine
was undertaken using single-cell sequencing [97]. With this method, the authors revealed
epithelial-like cells with genotypes (claudins, annexins, and endocytosis regulators) similar
to mammalian M-cells, and enterocytes expressing gene products that transduce inter-
feron pathway signals. After in-situ hybridization using a probe detecting the M-cell
marker icn (ictacalcin), it was evident that the M-like cells were localized in the posterior
region—analogous to the localization in mammalian colon. It should be noted that no
universal M-cell markers have been found [98], thus icn could be considered a zebrafish
M cell marker. This zebrafish study suggested that there are different cell populations in the
fish intestine, though not clearly visible from morphological and anatomical analysis. It has
been shown that IgM+ and IgT+ cells usually have been found in the lamina propria [99],
and IgT+ cells as intraepithelial cells [100]. However, following oral vaccination using
an alginate-encapsuled DNA vaccine (IPNV), IgM and IgT responses were found mainly
in the pyloric caeca [46]. The reason for the anatomical redistribution of IgT+ and IgM+
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cells after vaccination is not clear. Obviously, more targeted research should be performed
in order to find the exact responding site for antibody response in fish. This applies to
detailing the anatomical distribution of different cell populations in many fish species.
6.3. Lamina Propria Eosinophilic Granular Cells
In many fish species, eosinophilic granular cells (EGCs) are quite dominant cell
populations in the lamina propria (Figure 1), where they reside on both sides of stratum
compactum. Since they are numerous, they must possess an important role. It is suggested
that fish intestinal eosinophilic granular cells (EGCs) are homologous to mammalian mast
cells [101–105]. Rodlet cells, which share many characteristics with EGC, may be precursors
of EGC, as suggested by Reite and Evensen (2006) [102]. Whether all fish species possess
mast cells analogues with similar functions remains to be shown. Notwithstanding, the
number of EGCs increases during intestinal inflammation [102,106–108]. Mast cells of
perciformes are of special interest because they also contain antimicrobial peptides named
“piscidins” [109,110]. Furthermore, zebrafish mast cells have been found to express myd88
(toll-like receptor adaptor molecule) and FcRI, which is similar to IgE receptors in higher
vertebrates [111].
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6.4. Modulation of Intestinal Responses
It is clear that the intestine of fishes can respond immunologically. Studies of intestinal
mucous facto s must be carefully planned and executed to avoid ontaminant cells and
blood to avoid false ass mptions with regard to the actual presence f immune factors in
mucous secretion. The ame applies to the analysis of intestin l tissu , where most mucous
secretions hould be removed prior to assessment.
Transcriptomic and proteomic assessment of fish i estines will provide large datasets
that can be further refine to s udy intestinal r sp nse to, e.g., oral vaccination, infection,
and probioti s in a more targ ted way. From the refi ed dataset (e.g., differential expressed
gen s, proteins, c rrelates of protection or infection), the research community may select
central components decisive for given response or/a d protecti . Recently, there have
been any innovative approaches to better understanding intestinal immunity. In one
of these studies, proteomic and transcriptomic examination of the intestinal mucus in
Tilapia infected with S. agalactiae showed involvement of innate factors such as C1r-like EGF
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domain, C1q binding protein, heat shock protein 70 and 90b, galectin, membrane attack complex
component/perforin domain; conserved site, complement factor D, C-type lectin fold, il1, il1r, foxp3,
among others [84]. Another study involving grass carp conducted a transcriptomic and
proteomic examination of the intestine after oral DNA vaccination [112]. The study revealed
250 and 50 immune related DEGs and DEPs, respectively, after oral vaccination. KEGG
enrichment analysis showed that genes and proteins participating in the Toll-like receptor
signaling pathway, MAPK signaling pathway, NOD-like receptor signaling pathway, and
the complement cascade were present both in the mucous and tissue homogenates. It is
obvious that the innate intestinal mechanisms are quite diverse. More research using omics
technologies together with functional assessment will inevitably give us more information
about the significance of the various intestinal innate factors that have on innate disease
resistance. When it comes to intestinal response after oral vaccination, mucosal response
in terms of Ig response is indeed evident [28,113]. Muñoz-Atienza et al. (2021) made a
recent overview on mucosal B- and T-cell responses after mucosal vaccination of teleost
fish, which we advise the readers to read [2].
6.5. Oral Tolerance
Induction of immunological tolerance has been observed in orally vaccinated fish. The
cause is probably the activity of regulatory T-cells, as suggested by Marana et al. (2020) [114].
In this study, continuously feeding rainbow trout with a low dosage, Y. ruckeri bacterin
resulted in lower protection after experimental challenge compared with fish given an
initial high dose. Related findings in carp and seabream have been observed [115,116], and
in goldfish [25] after feeding protein antigens. It is suggested that primary immunization
by oral administration of antigens should be performed using a high initial dose of antigen.
7. Conclusions and Future Direction
There are numerous model vaccines that have evoked intestinal immune responses,
where Ig response seems to be a major component for protection. However, innate im-
mune mechanisms cannot be ruled out since findings underline that rag−/− zebrafish
(without IgM) possess similar protection as rag−/+ against experimental V. anguillarum
challenge. Furthermore, the composition of intestinal microbiota may be changed during
oral administration of antigens/plasmids, especially when these are entrapped in vaccine
carriers. It is known from studies in higher vertebrates that the gut microbiota may affect
vaccine efficacy. Thus, it is pertinent to study whether and how oral vaccination alters
intestinal microflora in fish. This also applies to how microbiota affects vaccine efficacy. The
maximum efficacy of oral vaccines depends on a prime-boost strategy, how the antigens
are protected, how immunogenic the antigens are and the dose. One should not expect
higher protection after oral immunization compared to immersion vaccination, indeed and
i.p. and i.m. vaccination.
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